The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS). The approval stipulates use of pegulicianine with the ...
Breast cancer is hard enough. Treatment should be quick and easy. That's the thinking of many physicians who have opted to offer MammoSite, a type of radiation that cuts treatment time from several ...
NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, today ...
SACRAMENTO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- The TARGIT Collaborative Group announced today that according to recent studies, an increase in the COVID-19 positivity rate correlates to an ...
Impact of surgery and radiation of the primary among women with de novo stage IV breast cancer. Impact of adjuvant chemotherapy on recurrence-free survival in patients with pT1a/b hormone-negative and ...
Phase I study of vinorelbine (VRL) alternating i.v. and oral in combination with docetaxel (DTX) as 1st line chemotherapy (CT) of metastatic breast cancer (MBC) No significant financial relationships ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results